HOYA Corporation (7741.T) vs Takeda Pharmaceutical Company Limited (TAK)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| 7741.T | TAK | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Drug Manufacturers - Specialty & Generic |
| Size band | LARGE | LARGE |
| Listing | Tokyo | NYSE |
| Country | Japan | Japan |
| Theme | vision-and-ophthalmology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | 26,100.00 JPY | $20.43 |
| Return · 1 week | +0.42% | +4.18% |
| Return · 1 month | +10.64% | +8.10% |
| Return · 3 months | +9.83% | +16.61% |
| Return · year to date | +8.89% | +30.79% |
| Return · 1 year | +7.88% | +44.18% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −14.14% | −0.59% |
| 52-week high | 30,400.00 JPY | $20.55 |
| 52-week low | 22,165.00 JPY | $12.99 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $55.11B | $65.27B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $30.83B | $48.63M |
| Employees | 37,752 | 47,029 |
| Valuation | ||
| Price to earnings · trailing | 31.62× | n/a (negative earnings) |
| Price to earnings · forward | 36.53× | 37.11× |
| Price to sales | 8.46× | 0.01× |
| Price to book | 8.22× | 1.30× |
| Enterprise value to EBITDA | 20.76× | 4.11× |
| Enterprise value to revenue | 8.14× | 1.11× |
| PEG ratio | 2.67 | 0.44 |
| Earnings per share · trailing | 789.18 | -0.34 |
| Profitability | ||
| Gross margin | 86.35% | 65.50% |
| Operating margin | 32.39% | 16.45% |
| Profit margin | 27.15% | −3.54% |
| Return on equity | 26.53% | −2.26% |
| Return on assets | 14.04% | 2.69% |
| Growth | ||
| Revenue growth | +16.20% | +10.20% |
| Earnings growth | +30.00% | −9.80% |
| Balance sheet and payout | ||
| Debt / equity (%) | 4.40 | 73.25 |
| Current ratio | 4.91 | 1.14 |
| Dividend yield | 1.16% | 3.13% |
| Payout ratio | 37.38% | 279.89% |
| Trend and volatility | ||
| RSI · 14 | 63.97 | 70.35 |
| ADX · 14 | 30.76 | 32.50 |
| 50-day average | 24,626.70 JPY | $18.59 |
| 200-day average | 26,184.35 JPY | $17.45 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.65% | 1.79% |
The full 7741.T analysis
Everything this table leaves out for HOYA Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the 7741.T argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full 7741.T analysisThe full TAK analysis
Everything this table leaves out for Takeda Pharmaceutical Company Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TAK argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TAK analysis